Thursday Nov 12 | Zacks Analyst Blog
Cypress Beats, but Loss Widens
Analyst Report ) reported a net loss of 14 cents per share in the third quarter, 6 cents better than the Zacks Consensus Estimate of a net loss of 20 cents.
Investment Thesis for Forest Laboratories, Inc.
All News and Columns >>>> Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products, which require a physician's prescription.
Forest Laboratories: Steady Growth in Sales and Earnings
I have written about Forest Laboratories, Inc. before. FRX is a mid-cap player in the biotech and drug markets.
Forest Labs Still Struggling To Meet Armour Thyroid Demand
GS_googleAddAdSenseService ; GS_googleEnableAllServices(); GA_googleUseIframeRendering(); _head> _script> NEWS Latest Archives Auto Cells, etc.
Ironwood, Forest 'Rooting' for Added Success In IBS
Ironwood Pharmaceuticals Inc. and partner Forest Laboratories Inc. reported positive results from two pivotal Phase III trials of its bowel drug candidate linaclotide in chronic constipation.
Ironwood and Forest Announce Positive Linaclotide Results from Two...
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation .
It's Not As Frightening As It First Appears
On the surface, Mylan 's earnings report wasn't pretty. Revenue fell by 24%, and the company lost $0.13 per share.
This morning, Forest Laboratories, Inc. , reported earnings per share of 85 cents for the second quarter of fiscal 2010, in-line with the Zacks Consensus Estimate.
Sun Pharma backs out of Forest patent row
The Mumbai-based drug firm has settled the matter with Forest Labs and has opted out of the case going on in the district court of Delaware, USA.
Forest Labs profit slides on drug costs
Forest Laboratories Inc. on Tuesday said its fiscal second-quarter profit fell 24 percent after it paid $100 million for the rights to market a chronic lung drug candidate.
Nibbles Here and There at Forest Labs
Pretend you're the CEO of a drug company approaching the dreaded "patent cliff." Products yielding significant sales will soon face generic competition, but you don't know if your home-grown drugs can pick up the slack.
Forest Labs' Shares Out of the Woods
WE BELIEVE THAT Forest Laboratories shares can outperform the market by 15% over the next 12 months, and we are raising our investment rating to Outperform [from Neutral]. Nonconsensus, positive feedback on multiple Forest pipeline drugs from our physician and regulatory consultants at our recent Therapeutic Categories conference improves our ...
Zacks Analyst Blog Highlights: Biogen Idec, Elan, UnitedHealth Group...
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Forest Labs outlook trails Street, shares sink
Drugmaker Forest Laboratories Inc posted a lower-than-expected quarterly profit on Tuesday and gave an outlook below analysts' forecasts, sending shares down 4.8 percent.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
Forest Laboratories Inc. F2Q10 Earnings Call Transcript
Ian Sanderson - Cowen & Co. Tim Chiang - FTN Ronny Gal - Sanford Bernstein & Co.
Earnings Watch: Updates, advisories and surprises
MGM Mirage Inc., /quotes/comstock/13*!mgm /quotes/nls/mgm the Las Vegas casino and hotels operator, expects to report a third-quarter pretax charge of $955 million before taxes for impairment of its investment in CityCenter, a project on the Las Vegas Strip that's scheduled to open late this year.
Forest Laboratories and Cypress Bioscience Announce Study Shows...
NEW YORK & SAN DIEGO - Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced that Savella 100 mg/day demonstrated statistically significant and clinically meaningful concurrent improvements in pain, patient global assessment, and physical function, according to results from a large-scale, Phase III clinical trial that will be ...
Targacept Unveils Stellar Depression Drug Data: BioBuzz
There are times when clinical data crosses the wire and you do a double take, not quite believing what you're seeing.
Targacept Unveils Depression Drug Data Next Week: BioBuzz
Investor expectations for Targacept's experimental depression drug are moving higher in lockstep with the company's stock price as a key data presentation nears.
Also on Topix